LUNG vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Pulmonx Corporation (LUNG) presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of positive earnings. While the company maintains strong short-term liquidity (Current Ratio 5.07) and impressive gross margins (74.19%), these are offset by negative revenue growth (-4.90%) and severe long-term price erosion (-96.7% over 5 years). The stark divergence between the analyst target price ($5.17) and the bearish insider activity suggests a speculative environment where fundamental deterioration outweighs theoretical upside.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
LUNG vs MRK: Head-to-Head Comparison
This page compares Pulmonx Corporation (LUNG) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.